We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
In its upcoming report, Danaher (DHR - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.64 per share, reflecting a decline of 4.7% compared to the same period last year. Revenues are forecasted to be $5.84 billion, representing a year-over-year increase of 1.6%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Danaher metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Total sales- Diagnostics' to come in at $2.28 billion. The estimate indicates a change of +1.1% from the prior-year quarter.
According to the collective judgment of analysts, 'Total sales- Life Sciences' should come in at $1.71 billion. The estimate suggests a change of -3.5% year over year.
Based on the collective assessment of analysts, 'Total sales- Biotechnology' should arrive at $1.83 billion. The estimate indicates a year-over-year change of +6.8%.
The consensus estimate for 'Operating profit- Life Sciences' stands at $206.51 million. Compared to the current estimate, the company reported $233.00 million in the same quarter of the previous year.
The average prediction of analysts places 'Operating profit- Biotechnology' at $463.69 million. The estimate is in contrast to the year-ago figure of $462.00 million.
The combined assessment of analysts suggests that 'Operating profit- Diagnostics' will likely reach $501.31 million. Compared to the current estimate, the company reported $556.00 million in the same quarter of the previous year.
Danaher shares have witnessed a change of -0.6% in the past month, in contrast to the Zacks S&P 500 composite's +4.2% move. With a Zacks Rank #4 (Sell), DHR is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Danaher (DHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Danaher (DHR - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.64 per share, reflecting a decline of 4.7% compared to the same period last year. Revenues are forecasted to be $5.84 billion, representing a year-over-year increase of 1.6%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Danaher metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Total sales- Diagnostics' to come in at $2.28 billion. The estimate indicates a change of +1.1% from the prior-year quarter.
According to the collective judgment of analysts, 'Total sales- Life Sciences' should come in at $1.71 billion. The estimate suggests a change of -3.5% year over year.
Based on the collective assessment of analysts, 'Total sales- Biotechnology' should arrive at $1.83 billion. The estimate indicates a year-over-year change of +6.8%.
The consensus estimate for 'Operating profit- Life Sciences' stands at $206.51 million. Compared to the current estimate, the company reported $233.00 million in the same quarter of the previous year.
The average prediction of analysts places 'Operating profit- Biotechnology' at $463.69 million. The estimate is in contrast to the year-ago figure of $462.00 million.
The combined assessment of analysts suggests that 'Operating profit- Diagnostics' will likely reach $501.31 million. Compared to the current estimate, the company reported $556.00 million in the same quarter of the previous year.
View all Key Company Metrics for Danaher here>>>Danaher shares have witnessed a change of -0.6% in the past month, in contrast to the Zacks S&P 500 composite's +4.2% move. With a Zacks Rank #4 (Sell), DHR is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .